Sodium-glucose co-transport inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus

Drugs

Volumn 70, Issue 4, 2010, Pages 377-385

  Neumiller, Joshua J ^a   White, John R ^a   Campbell, R Keith ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; METFORMIN; PHLORIZIN; PLACEBO; REMOGLIFLOZIN; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; GLUCOSURIA; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; URINARY FREQUENCY; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 77949287535     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318680-000000000-00000     Document Type: Review

References (49)

1. American Diabetes Association. All about diabetes [online]. Available from URL: http://www.diabetes.org/about-diabetes. jsp [Accessed 2009 Oct 10]
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008
3. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
4. Moss SE, Klein R, Klein BE, et al. The association of glycemia and cause specific mortality in a diabetic population. Arch Intern Med 1994; 154: 2473-2479
5. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772
6. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008; 18: 222-229
7. Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin 2008; 26: 639-648
8. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531-537
9. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258
10. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012
11. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Eur J Physiol 2004; 447: 510-518
12. Kanai Y, Lee W-S, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. J Clin Invest 1994; 93: 397-404
13. Asano T, Anai M, Sakoda H, et al. SGLT as a therapeutic target. Drugs Fut 2004; 29: 461-466
14. Asano T, Ogihara T, Katagiri H, et al. Glucose cotransporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem 2004; 11: 2717-2724
15. Gerich JE, Woerle HJ, Meyer C, et al. Renal gluconeogenesis. Diabetes Care 2001; 24 (2): 382-391
16. Guyton AC, Hall JE. Textbook of medical physiology. 9th ed. Philadelphia (PA): W.B. Saunders Company, 1996: 316
17. Gullans SR. Metabolic basis of solute transport. In: Brenner BM, editor. Brenner and Rector's, the kidney. 6th ed. Philadelphia (PA): W.B. Saunders Company, 2000: 234-235
18. Stumvoll M, Meyer C, Mitrakou A, et al. Renal glucose production and utilization: new aspects in humans. Diabetologia 1997; 40: 749-757
19. Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102: 619-624
20. Guyton AC, Hall JE. Textbook of medical physiology. 9th ed. Philadelphia (PA): W.B. Saunders Company, 1996: 332-335
21. +-glucose transporters. Am J Physiol Renal Physiol 2001; 280: F10-8
22. Butterfield WJH, Keen H, Whichelow MJ. Renal glucose threshold variations with age. BMJ 1967; 4: 505-507
23. Moe OW, Berry CA, Rector FC. Renal transport of glucose, amino acids, sodium, chloride, and water. In: Brenner BM, editor. Brenner and Rector's, the kidney. 6th ed. Philadelphia (PA): W.B. Saunders Company, 2000: 378-380
24. Bakris GL, Fonseca V, Sharma K, et al. Renal sodiumglucose transport: role in diabetes mellitus and potential clinical implications. Kidney International 2009; 75: 1272-1277
25. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43
26. Abdul-Ghani MA, DeFronzo R. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Practice 2008; 14 (6): 782-790
27. Stumvoll M, Chintalapudi U, Perriello G, et al. Uptake and release of glucose by the human kidney: postabsorptive rates and responses to epinephrine. J Clin Invest 1995; 96: 2528-2533
28. Meyer C, Dostou JM, Welle SL, et al. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Met 2002; 282: E419-27
29. Ehrenkranz RRL, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31-38
30. Dudash Jr J, Zhang X, Zeck RE, et al. Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporters 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 2004; 14: 5121-5125
31. Chassis H, Joliffe N, Smith H. The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 1933; 12: 1083-1089
32. Lee WS, Wells RG, Hediger MA. The high affinity NA/ glucose cotransporter: re-evaluation and distribution of expression. J Biol Chem 1994; 269: 12032-12039
33. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009; 11: 79-88
34. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657
35. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883
36. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular re-absorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-1284
37. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharm Ther 2009; 85: 520-524
38. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mel-litus. Clin Pharm Ther 2009; 85: 513-519
39. Bailey CJ, Gross JL, Bastone L, et al. Dapagliflozin as an add-on to metformin lowers hyperglycemia in type 2 diabetes patients inadequately controlled with metformin alone [abstract no. OP169]. Diabetologia 2009; 52 Suppl. 1: S76
40. Wilding JPH, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Diabetes Care 2009; 32: 1656-1662
41. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Oct 10]
42. Lesli B, Tang W, List JF. Renal effects of the sodiumglucose co-transporter 2 (SGLT2) inhibitor depagliflozin (BMS-512148) in patients with type 2 diabetes mellitus (T2DM) [abstract no. PO1022]. J Am Soc Nephrol 2008; 19
43. Kissei Pharmaceutical Co., Ltd. Discontinuation of the development of "Remogliflozin" by GlaxoSmithKline [online]. Available from URL: http://www.kissei.co.fp/e-contents/ press-e/2009/e20090703.html [Accessed 2009 Oct 10]
44. Colca JR. Discontinued drugs in 2008: endocrine and metabolic. Exp Opin Invest Drugs 2009; 18: 1243-1255
45. Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglyce-mia in streptozotocin-induced diabetic rats. Metabolism 2000; 49: 990-995 (Pubitemid 30641434)
46. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucosa cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-330
47. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729
48. Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-276
49. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149